HUGE HUGE ALRET EKG.V
FDA Approves the First Ever Over-the-Counter Heart Monitoring Solution
EKG.V CURRENT PRICE: $0.13
EKG.V TARGET PRICE: $14.11
UPSIDE POTENTIAL: 10,754%
SHARES OUTSTANDING: 77,436,440
January 22, 2012 - Toronto, Ontario - CardioComm Solutions, Inc. (TSXV:EKG) rose 200% on Friday after the FDA approved their consumer-based, hand-held heart rhythm monitor known as the HeartCheck™ Pen Handheld ECG. This is the first ever heart monitor that has been approved for over-the-counter sales and marketing purposes.
See the full release here
The company has 77.4M shares outstanding and 19 million warrants to be exercised at 10 cents. Assuming all the warrants will get exercised that would increase the share total to 96.4M with a $1.9M cash infusion to the company. With a share price of 13 cents that would assume a mere $12.5 market cap or $10.6M of enterprise value.
27.1M people in the United States alone suffer from heart disease. Assuming only 5% of these people buy the HeartCheck™ Pen Handheld ECG in the first year that would be 1.36M devices sold. If each device were to sell for $100, that would imply $136M of revenue in the first year alone.
A 50% margin would be conservative for a company with a patent on the first ever Over-the-Counter heart monitor, essentially becoming a monopoly in this very important niche. A 50% margin on $136M of revenue is $68M in net profit. Applying a very conservative 20 Price to Earnings multiple to this figure would imply a $1,360M enterprise value.
Dividing $1,360M in enterprise value by 96.4M shares outstanding would imply a price per share of $14.11, assuming that only 5% of Americans diagnosed with heart disease purchase this extremely useful tool in the first year it is on the market. This assumes no other sales from Canada or any other country and given America's aging population and high rates of obesity, the HeartCheck™ Pen sales are very likely to increase each year. CardioComm Solutions is vastly undervalued at its current share price
